The Car­lyle Group shells out $435M for con­trol­ling stake in vac­cine, gene ther­a­py ser­vices com­pa­ny

The Car­lyle Group has put a tar­get on life sci­ences in re­cent years, look­ing for op­por­tu­ni­ties to take con­trol­ling stakes in promis­ing firms. Af­ter shelling out near­ly half-a-bil­lion dol­lars last year on a one-fifth stake in an In­di­an CD­MO, the DC in­vestors have their eyes set on a com­pa­ny spe­cial­iz­ing in vac­cine and gene ther­a­py ser­vices.

Car­lyle shelled out $435 mil­lion to ac­quire more than 90% of Un­chained Labs, a six-year-old Cal­i­for­nia-based firm, from Dan­ish as­set man­ag­er No­vo Hold­ings and VC firms TPG Biotech and Canaan Part­ners.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER